Pursuing Innovation In A Changing China
This article was originally published in PharmAsia News
Pharmaceutical companies in China have no doubt felt the chill over the past two years from authorities’ eagerness to reshape the industry with stricter regulations and compliance requirements. But does China have the framework in place to encourage innovation?
You may also be interested in...
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.